1. Home
  2. PENG vs GHRS Comparison

PENG vs GHRS Comparison

Compare PENG & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Penguin Solutions Inc. Ordinary Shares

PENG

Penguin Solutions Inc. Ordinary Shares

HOLD

Current Price

$49.98

Market Cap

959.2M

Sector

Technology

ML Signal

HOLD

Logo GH Research PLC

GHRS

GH Research PLC

HOLD

Current Price

$22.13

Market Cap

947.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PENG
GHRS
Founded
1988
2018
Country
United States
Ireland
Employees
2900
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
959.2M
947.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PENG
GHRS
Price
$49.98
$22.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
8
Target Price
$27.78
$41.38
AVG Volume (30 Days)
2.6M
251.0K
Earning Date
04-01-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.55
N/A
Revenue Next Year
$16.14
N/A
P/E Ratio
$87.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.04
$10.67
52 Week High
$53.27
$24.66

Technical Indicators

Market Signals
Indicator
PENG
GHRS
Relative Strength Index (RSI) 90.35 64.04
Support Level $18.38 $12.41
Resistance Level N/A $22.88
Average True Range (ATR) 3.34 1.32
MACD 1.51 -0.04
Stochastic Oscillator 86.38 76.22

Price Performance

Historical Comparison
PENG
GHRS

About PENG Penguin Solutions Inc. Ordinary Shares

Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: